Financial Performance - The company's operating revenue for 2021 was approximately ¥438.99 million, representing a year-over-year increase of 16.93% compared to ¥375.43 million in 2020[22]. - The net profit attributable to shareholders for 2021 was approximately ¥79.78 million, a decrease of 5.86% from ¥84.75 million in 2020[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥62.78 million, down 11.28% from ¥70.76 million in 2020[22]. - The net cash flow from operating activities for 2021 was approximately ¥59.61 million, a decline of 34.79% compared to ¥91.43 million in 2020[22]. - The comprehensive gross profit margin for 2021 was 77.92%, a decrease of 1.85 percentage points compared to 2020, primarily due to an increase in the proportion of purchased products[126]. - Revenue from external diagnostic products was 437.44 million yuan, with a gross profit margin of 77.94%, reflecting a year-on-year increase of 16.79%[128]. - Service revenue saw a significant increase of 255.34%, reaching 16.78 million yuan, indicating successful expansion in service offerings[128]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 2.70 CNY per 10 shares, totaling approximately 25,201,800 CNY, which represents 31.59% of the net profit attributable to shareholders for 2021[6]. - The company’s profit distribution plan has been approved by the board and is pending approval from the shareholders' meeting[6]. Audit and Compliance - The company has received a standard unqualified audit report from Zhonghui Certified Public Accountants[5]. - The company has detailed potential risks in its annual report, which can be found in the section discussing operational conditions and risk factors[4]. - There are no non-operating fund occupations by controlling shareholders or related parties[8]. - The company has not violated decision-making procedures for providing guarantees[9]. - The company has not reported any special arrangements for corporate governance[9]. Research and Development - R&D investment reached 45.90 million yuan, up 65.52% year-on-year, accounting for 10.46% of operating revenue[33]. - The total R&D investment for the year was approximately ¥45.90 million, representing a 65.52% increase compared to the previous year's ¥27.73 million[87]. - The company has established a dedicated R&D team of 148 people, accounting for 21.23% of total employees, and has participated in multiple national and provincial research projects to enhance its technological innovation capabilities[102]. - The company is focusing on enhancing R&D efforts in tumor screening and diagnosis across multiple technology platforms[88]. Market and Product Development - The company has developed a comprehensive solution for cervical cancer screening, integrating cytology and HPV molecular testing, which significantly improves specimen satisfaction and detection rates compared to traditional methods[97]. - The company is actively developing a cervical cytology AI-assisted diagnostic product in collaboration with Tencent, aiming to establish industry standards for cervical liquid-based cytology databases[66]. - The company is focusing on the development of automated, standardized, digitalized, and intelligent pathology departments, integrating cutting-edge technologies such as big data and cloud computing[66]. - The company has developed 570 registered/recorded pathology diagnosis-related products, making it one of the most comprehensive technology platforms in the domestic tumor screening and diagnosis industry[63]. Strategic Partnerships and Collaborations - The company has established a strategic partnership with Tencent AILab to develop AI-assisted diagnostic products for cervical cytology[31]. - The company is exploring collaborative models to enhance pathology services in grassroots hospitals, addressing the uneven distribution of pathology resources in China[75]. - The company has established partnerships with leading pathology experts to enhance its research capabilities and project execution[102]. Risks and Challenges - The company faces risks related to new product development and registration, which are critical for maintaining its market position[111]. - The company anticipates increased market competition and potential price declines for its cervical cancer screening products due to industry maturation[114]. - The company faces risks related to accounts receivable collection due to rapid growth in sales, with accounts receivable aging typically within one year[118]. Governance and Management - The company has maintained a stable leadership structure, with all directors and key technical personnel holding their positions since their appointment dates[181]. - The company has a diverse management team with extensive experience in various sectors, ensuring a robust governance structure[183]. - The board of directors attended 10 meetings in total, with all members present at each meeting[195]. Investment and Acquisitions - The company made significant equity investments in 2021, including 100% ownership in multiple subsidiaries focused on sales and medical diagnostics[154]. - The company is actively expanding its market presence through strategic investments in diagnostic and medical service companies[155]. - The company has established multiple investment partnerships, with ownership stakes ranging from 9.09% to 100% in various entities[154]. Sales and Marketing - The company has established a nationwide marketing network with over 1,900 clients, including 976 tier-three hospitals[169]. - The company is focusing on developing distribution channels, resulting in a faster growth rate in distribution sales compared to direct sales[132]. - The company’s marketing strategy emphasizes a "direct sales as primary, distribution as supplementary" model, enhancing customer engagement through training and technical support[37].

一、 主要财务数据 2021 年第三季度报告 证券代码：688393 证券简称：安必平 广州安必平医药科技股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 注:"本报告期"指本季度初至本季度末 3 个月期间，下同。 (二)非经常性损益项目和金额 (一)主要会计数据和财务指标 单位：元 币种：人民币 单位：元 币种：人民币 | 项目 | 本报告期金额 | 年初至报告期末金额 | 说明 | | --- | --- | --- | --- | | 非流动性资产处置损 益（包括已计提资产减 | -48,729.55 | 311,449.16 | | | 值准备的冲销部分） 计入当期 ...

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2021, representing a 20% increase compared to the same period last year[12]. - The company's operating revenue for the first half of 2021 was CNY 212,376,439.30, representing a 46.65% increase compared to CNY 144,820,362.67 in the same period last year[18]. - The net profit attributable to shareholders was CNY 50,880,437.99, a 56.09% increase from CNY 32,596,311.84 year-on-year[18]. - The company reported a total revenue of 129,561,215.0 RMB for the first half of 2021, with a net profit of 15,219,824.6 RMB, representing a significant increase compared to the previous period[44]. - The company achieved operating revenue of CNY 212.38 million in the first half of 2021, representing a year-on-year growth of 46.65%[72]. - Net profit attributable to shareholders reached 50.88 million yuan, up 56.09% year-on-year[72]. - The net profit after deducting non-recurring gains and losses was 44.26 million yuan, an increase of 41.99% compared to the previous year[72]. Research and Development - The company is investing 30 million CNY in R&D for new technologies aimed at enhancing diagnostic accuracy and efficiency[12]. - The research and development expenditure accounted for 7.17% of operating revenue, a decrease of 0.61 percentage points from the previous year[20]. - The company achieved a total R&D investment of ¥15,219,824.64, representing a 35.11% increase compared to ¥11,264,515.31 in the previous period[39]. - Research and development expenses totaled CNY 15.22 million, reflecting a 35.11% increase year-on-year, accounting for 7.17% of operating revenue[61]. - The company has developed a new reagent consumable for the LBP-5548 fully automatic immunohistochemistry staining machine, improving reagent usage efficiency[36]. - The company is developing AI-assisted diagnostic products, including a cervical pathology diagnosis system, which is currently under registration for medical device certification[43]. - The company has established three major technology platforms: cytological diagnosis, molecular diagnosis, and immunodiagnosis, covering various clinical diagnostic needs[29]. Market Expansion and Strategy - The company has provided a performance guidance for the second half of 2021, expecting a revenue growth of 25% year-over-year[12]. - Market expansion plans include entering two new provinces, targeting a 10% market share within the first year of operation[12]. - The company aims to expand its market presence through the development of innovative diagnostic technologies and strategic partnerships[47]. - The company has established partnerships with two grassroots medical institutions to co-build pathology departments, aiming to enhance the service capabilities of county-level hospitals[65]. - The company is focusing on expanding its marketing network to grassroots hospitals and third-party testing institutions, with new subsidiaries established in Chongqing, Anhui, and Hunan[63]. Product Development and Innovation - New product launches include a state-of-the-art diagnostic kit, projected to contribute an additional 50 million CNY in revenue by year-end[12]. - The company has developed over 500 products covering various cancer types, including cervical cancer, breast cancer, and lung cancer, utilizing core technologies such as LBP, PCR, FISH, and IHC[50]. - The company’s products are designed to meet the needs of different levels of medical institutions, ensuring a comprehensive product line[29]. - The company has successfully integrated its self-developed instruments with its reagents, achieving automated batch processing and stable quality[30]. - The company has launched three major brands for its automated staining equipment, achieving comprehensive coverage of different customer needs[34]. Financial Position and Assets - The company's total assets increased by 0.69% to CNY 1,301,105,278.68 compared to CNY 1,292,250,751.64 at the end of the previous year[19]. - As of the end of the reporting period, the company's total assets amounted to CNY 1,301.11 million, with net assets attributable to shareholders of CNY 1,172.67 million, indicating a solid financial position[60]. - The company reported a total current asset of CNY 994,316,320.55, down from CNY 1,028,196,554.47, a decrease of about 3.3%[138]. - The company’s cash and cash equivalents decreased to CNY 494,107,999.88 from CNY 622,544,392.72, a decline of approximately 20.6%[137]. - The company’s total liabilities reached CNY 134,536,250.63, compared to CNY 124,667,352.15, marking an increase of around 7.0%[134]. Risks and Challenges - The company has identified potential risks including regulatory changes and market competition, which are detailed in the risk factors section of the report[4]. - The company faces risks related to increased market competition and potential price declines for its cervical cancer screening products due to intensified competition and policy implementations[68]. - The company is facing risks related to customer diversification and sales model differences compared to industry peers[69]. Shareholder and Governance - The board confirmed that there are no non-operational fund occupations by controlling shareholders or related parties[4]. - The company has implemented an equity incentive plan to align the interests of shareholders, the company, and core team members, enhancing motivation and creativity[61]. - The controlling shareholder and actual controller, Cai Xiangting, committed to not transferring or entrusting the management of shares for 36 months from the date of the company's stock listing[96]. - The company ensures that any share reduction will be conducted in compliance with the regulations set by the China Securities Regulatory Commission and the Shanghai Stock Exchange[98]. Compliance and Legal Matters - The company has not reported any significant litigation or arbitration matters during the reporting period[107]. - The company has not disclosed any temporary announcements related to significant transactions[110]. - The company has not reported any violations or penalties involving its directors, supervisors, or senior management[107].

Financial Performance - Operating revenue surged by 158.72% to CNY 99,508,003.08 year-on-year[7] - Net profit attributable to shareholders increased by 169.87% to CNY 26,664,570.54 compared to the same period last year[7] - Basic earnings per share rose by 107.14% to CNY 0.29[7] - The company's operating revenue for Q1 2021 reached ¥99,508,003.08, representing a 158.72% increase compared to ¥38,461,902.33 in Q1 2020, primarily due to a significant increase in sales volume[14] - Net profit for Q1 2021 was ¥26,233,758.61, representing a 189.5% increase from ¥9,064,366.31 in Q1 2020[29] - Net profit for Q1 2021 was ¥21,729,658.91, representing a 143.5% increase from ¥8,942,163.07 in Q1 2020[32] Cash Flow - Net cash flow from operating activities improved significantly to CNY 1,564,154.14, compared to a negative CNY 2,207,715.69 in the previous year[7] - The net cash flow from operating activities improved to ¥1,564,154.14, a significant recovery from a negative cash flow of -¥2,207,715.69 in Q1 2020, driven by increased sales collections and government subsidies[14] - The company recorded a net increase in cash and cash equivalents of ¥27,720,827.30 in Q1 2021, contrasting with a decrease of ¥22,129,118.89 in Q1 2020[36] - The company reported a cash flow from operating activities of ¥1,564,154.14, a turnaround from a negative cash flow of ¥2,207,715.69 in Q1 2020[36] Assets and Liabilities - Total assets increased by 1.94% to CNY 1,317,292,767.74 compared to the end of the previous year[7] - The company's total assets amounted to 1,317.29 million CNY, an increase from 1,292.25 million CNY at the end of 2020[22] - The company's total current assets reached 1,073.81 million CNY, compared to 1,062.92 million CNY at the end of 2020, reflecting a growth of approximately 1.7%[20] - The company's total liabilities decreased by 60.90% in employee compensation payable, dropping to ¥5,496,480.43 from ¥14,058,838.44, reflecting the impact of year-end bonus provisions from the previous year[13] - Total liabilities increased to ¥141,989,765.76 from ¥139,333,798.27, a rise of 1.2%[26] Shareholder Information - The total number of shareholders reached 7,956 by the end of the reporting period[10] - The largest shareholder, Cai Xiangting, holds 21.23% of the shares, totaling 19,817,000 shares[10] Research and Development - R&D expenditure as a percentage of operating income decreased by 4.95 percentage points to 6.10%[7] - Research and development expenses increased by 42.81% to ¥6,071,613.10 from ¥4,251,649.33, indicating a focus on enhancing product development[14] - Research and development expenses for Q1 2021 were ¥6,071,613.10, compared to ¥4,251,649.33 in Q1 2020, an increase of 43.0%[28] Tax and Other Expenses - The company’s tax expenses rose by 202.02% to ¥5,021,825.47 from ¥1,662,723.83, reflecting increased profitability[14] - Sales expenses increased to ¥31,769,298.09 in Q1 2021, compared to ¥8,376,673.96 in Q1 2020, reflecting expanded marketing efforts[32] Incentive Plans - The company approved a restricted stock incentive plan to grant 2.00 million shares, representing 2.14% of the total share capital, with an initial grant of 1.70 million shares (1.82% of total share capital) and a reserve of 0.30 million shares (0.32% of total share capital) [15] - The first grant date for the restricted stock was set for February 8, 2021, with a grant price of 31.00 CNY per share for 170.30 thousand shares to 129 incentive recipients [16]

Financial Performance - The company's operating revenue for 2020 was CNY 375,433,111.72, representing a year-over-year increase of 5.71% compared to CNY 355,159,969.62 in 2019[21]. - Net profit attributable to shareholders for 2020 was CNY 84,745,713.59, reflecting a 14.54% increase from CNY 73,988,897.22 in 2019[21]. - The company's total assets at the end of 2020 reached CNY 1,292,250,751.64, a significant increase of 140.21% from CNY 537,961,728.25 in 2019[21]. - Basic earnings per share for 2020 were CNY 1.09, up 2.83% from CNY 1.06 in 2019[22]. - The company's total profit reached CNY 99,853,025.37, an increase of 14.45% compared to the previous year[107]. - The operating cost increased to CNY 75,964,151.22, reflecting a significant rise of 31.10% from the previous year[109]. - The company's comprehensive gross profit margin for 2020 was 79.77%, a decrease of 3.92 percentage points compared to 2019[111]. - The revenue from self-produced products was CNY 336,619,815.39, with a gross margin of 83.92%, down by 2.81 percentage points year-on-year[112]. - The revenue from purchased products was CNY 33,226,096.32, with a gross margin of 39.50%, decreasing by 7.64 percentage points compared to the previous year[112]. Research and Development - The company's R&D expenditure as a percentage of operating revenue increased to 7.39% in 2020 from 6.15% in 2019, indicating a focus on innovation[22]. - The company achieved a total R&D investment of ¥27,732,236.90, representing a 26.87% increase compared to the previous year[58]. - R&D investment accounted for 7.39% of total operating revenue, up from 6.15% in the previous year, indicating a 1.24 percentage point increase[58]. - The company has a high-quality R&D team of over 110 members, accounting for 21.44% of total employees, and has established an effective innovation mechanism to enhance its technological capabilities[72]. - The company is focused on improving the efficiency and quality of work for pathologists through innovative solutions[62]. Product Development and Market Position - The company operates in the high-tech pharmaceutical sector, focusing on medical technology and automation[13]. - The company has established three major technology platforms for in vitro diagnostics, covering cytology, molecular diagnostics, and immunodiagnostics[32]. - The company has developed several core technologies, including sedimentation liquid-based cytology and real-time fluorescence PCR preparation technology, enhancing its product offerings[32]. - The company has developed a PCR reagent kit capable of detecting 18 HPV subtypes simultaneously with high sensitivity and low amplification bias[51]. - The company has launched a series of automated pathology diagnostic instruments, including a fully automated sample processing machine and a fully automated immunohistochemistry staining machine[53]. - The company has developed a comprehensive cervical cancer screening solution that integrates cytological and HPV testing methods, significantly improving specimen satisfaction and detection rates compared to traditional methods[68]. Market Strategy and Expansion - The company aims to become a leading player in the domestic in vitro diagnostic field by focusing on product innovation and expanding its product application range[140]. - The marketing strategy includes building a direct sales network across various levels of medical institutions and expanding into rapidly growing grassroots hospitals and third-party testing institutions[143]. - The company will explore international markets when conditions are favorable to achieve global product reach[143]. - The company has established a marketing network covering nearly 1,800 medical institutions across 31 provinces, with direct sales accounting for over 60% of its sales model[35]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from Zhonghui Certified Public Accountants[5]. - The board of directors has confirmed the authenticity, accuracy, and completeness of the annual report[4]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[8]. - The company has not indicated any special arrangements in corporate governance[8]. - The company will ensure that related party transactions are conducted at fair market prices to protect the interests of shareholders[169]. Risks and Challenges - The company has outlined potential risks in its operations, which are detailed in the report[4]. - The company faces risks related to the inability to keep up with industry trends in product development, which could impact future growth potential[92]. - The company is exposed to risks from increased competition in the in vitro diagnostics market, with new entrants and existing competitors enhancing their capabilities[101]. - The company acknowledges the risk of core technology leakage and the potential loss of key technical personnel, which could impact future development capabilities[94]. Dividend Policy - The company plans to distribute a cash dividend of 2.80 RMB per 10 shares, totaling approximately 26,135,200 RMB, which represents 30.84% of the net profit attributable to shareholders for 2020[6]. - The profit distribution plan was approved by the board and supervisory committee, with independent directors expressing clear agreement[151]. - The company has a profit distribution policy that mandates at least 20% of the distributable profit to be allocated for cash dividends if the audited net profit is positive[147]. Financial Position and Assets - The company achieved a total asset of 1,292.25 million yuan and a net asset of 1,167.97 million yuan by the end of the reporting period, indicating a solid financial position[82]. - The company's cash and cash equivalents increased significantly to ¥635,270,871.63, representing 49.16% of total assets, up from 15.93% in the previous period, a growth of 641.29%[129]. - The company's receivables from accounts rose to ¥184,749,414.65, accounting for 14.3% of total assets, an increase of 9.04% compared to the previous period[130]. - The company's fixed assets reached ¥54,496,950.86, representing 4.22% of total assets, with a notable increase attributed to fundraising for R&D investments[130].

2020 年第三季度报告 公司代码：688393 公司简称：安必平 广州安必平医药科技股份有限公司 2020 年第三季度报告 1 / 28 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 8 | | 四、 | 附录 | 11 | 2020 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人蔡向挺、主管会计工作负责人陈泽龙及会计机构负责人（会计主管人员）黄爱萍 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 3 / 28 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度末增 减(%) 总资产 1,239,495,993.32 537,961,728.25 130.41 归属于上市公司 股东的净资 ...